Drug and Gene Delivery Devices Market is Estimated to Witness High Growth Owing to Opportunity in Personalized Medicine

Drug and gene delivery devices are medical tools used for targeted delivery of therapeutic agents like drugs, biologics and gene therapies inside the body. These devices facilitate controlled and sustained release of drugs at the site of disease, reduce dosing frequency and improve patient compliance. The devices shield therapeutic agents from external environment and ensure safe delivery to target cells and tissues. They are widely used in chronic disease management, tissue engineering and regenerative medicine.

The global Drug and Gene Delivery Devices Market is estimated to be valued at US$ 169.3 billion in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

Advancements in personalized medicine have created new opportunities for targeted drug and gene delivery. Personalized therapies are designed to treat individual patients based on their genetic profile and expected response to treatments. Drug and gene delivery devices facilitate precision targeting of therapies to specific cells and tissues, minimizing off-target effects. This improves efficacy and safety of personalized therapies. Growing emphasis on personalized treatment of cancer, genetic and neurodegenerative disorders is expected to drive high demand for advanced drug and gene delivery devices in the coming years.

Porter's Analysis

Threat of new entrants: The drug and gene delivery devices market has moderate threat of new entrants due to the presence of stringent regulations for product approval and high research and development costs.

Bargaining power of buyers: The bargaining power of buyers is moderate as there are numerous established players operating in this market providing a variety of products. However, high costs associated with these devices increase buyer's bargaining power.

Bargaining power of suppliers: The bargaining power of suppliers is moderate since key raw material components are available and there are multiple suppliers. However, supplier concentration for certain critical components increases their power.

Threat of new substitutes: Threat from new substitutes is low as drug and gene delivery devices have limited substitutes given their unique clinical applications and advantages over traditional treatment methods.

Competitive rivalry: The market witnesses high competitive rivalry owing to the presence of numerous global and regional players offering similar product portfolios. Players compete based on product differentiation, pricing, and brand value.

SWOT Analysis

Strengths: Non-invasive nature of drug and gene delivery devices, targeted drug delivery reducing side-effects, growing R&D activities.

Weaknesses: High costs associated, limited patient acceptability, delivery challenges associated with larger molecules.

Opportunities: Increasing prevalence of chronic diseases, rising pharmaceutical industry investment, developments in material sciences.

Threats: Stringent government regulations, reimbursement issues, manufacturing challenges.

Key Takeaways

The Global Drug And Gene Delivery Devices Market Size is expected to witness high growth during the forecast period owing to rising disease burden and growing adoption of advanced therapeutic methods. The global Drug and Gene Delivery Devices Market is estimated to be valued at US$ 169.3 billion in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023-2030.

North America dominates the market and is expected to continue its leading position over the next few years due to rise in healthcare expenditure, presence of major players, and supportive reimbursement policies in the region.Europe holds the second largest market share due to rising R&D activities and technological advancements in drug delivery. The Asia Pacific region is projected to grow at the fastest pace during the forecast period. This is attributed to increasing patient pool, growing healthcare spending, and rising awareness about advanced therapeutics in the region. China dominates the Asia Pacific market owing to occurrence of large patient population and improving healthcare infrastructure in the country.

Key players:

Key players operating in the drug and gene delivery devices market are 3D Systems Corporation, Cyfuse Biomedical KK, GeSIM GmbH, 3D Bioprinting Solutions, Aspect Biosystems Ltd., Organovo Holdings Inc., ARCAM AB (GE Company), Cellink AB, RegenHU SA, REGEMAT 3D, EnvisionTEC GmbH and Stratasys Ltd. 3D Systems Corporation, ARCAM AB (GE Company), and Stratasys Ltd are some of the leading players in the market.

​

For More Insights, Read: https://www.newswirestats.com/drug-and-gene-delivery-devices-market-demand-growth-and-regional-outlook-by-2030/